Daily functional treatment consisted of seven fish oil softgels (1.7g EPA+DHA), two dark chocolate truffles containing plant sterol esters and two green tea sachets.

Control treatment consisted of seven soy bean oil softgels, two regular dark chocolate truffles and two anise tea sachets

Cardiovascular Diseases

Omega 3 fatty acids, plant sterols and polyphenols

Functional treatment

Control treatment

Combined Bioactive Therapy Effects Over Cardiovascular Markers in Statin Treated Patients

Complementary Therapy of Omega 3 Fatty Acids, Plant Sterols and Polyphenols Over Cardiovascular Markers in Statin Treated Patients

Adriana Bertolami

MD. PhD

Instituto Dante Pazzanese de Cardiologia

Cardiovascular Disease, Inflammation

High DHA

High EPA

Placebo

Institute of Nutrition and Functional Foods (INAF), Laval University

Impact of EPA and DHA Supplementation on Plasma Biomarkers of Inflammation (n3)

Impact of EPA and DHA Supplementation on Plasma Biomarkers of Inflammation in Men and Women With Metabolic Syndrome

Change between treatments based on post-treatment values, adjusting for treatment-specific baseline values

Change between treatments based on post-treatment values

Benoit Lamarche

Professor

Laval University

Canadian Institutes of Health Research (CIHR)

Cardiovascular Disease

60g Canola oil daily per 3000kcal diet provided in a supplemental shake

Canola Oil

60g high oleic acid canola oil + DHA daily per 3000kcal provided in a supplemental shake

High Oleic Acid + DHA Canola Oil

60g high oleic acid canola oil daily per 3000kcal provided in a supplemental shake

High Oleic Acid Canola Oil

36g flax oil + 24g safflower oil daily per 3000kcal provided in a supplemental shake

Flax Oil

45g safflower oil + 15g corn oil daily per 3000kcal provided in a supplemental shake

Safflower Oil

Penn State University

Canola Oil Multicentre Intervention Trial (COMIT)

Canola and Flax Oils in Modulation of Vascular Function and Biomarkers of Cardiovascular Disease Risk

Study subjects will undergo endothelial health assessment by EndoPAT analysis. The EndoPat procedure will occur while the subject is lying down in a relaxed state. Throughout the study, the inflation pressure of the EndoPAT device will be electronically set to 10mm Hg below diastolic BP. Testing begins with 10 min of rest. Following rest, baseline pulse amplitude is measured from each fingertip for 5 min. Next, arterial flow is interrupted for 5 min by a cuff placed on the forearm at an occlusion pressure of 250 mmHg. Following occlusion release, pulse amplitude recording continues for 5 min.

To assess regional changes in body fat deposition, subjects will undergo a dual energy X-ray absorptiometry (DXA) scan at baseline (beginning of study) and end of each intervention period. Waist circumference measurements also will be taken at this time to track how much fat is lost from the abdominal area of the body.

On the 29th day of each diet phase you will be asked to consume three tablespoons of tagged water (known as deuterium). The movement of these tagged materials will allow us to assess the quantity of long chain fatty acids (EPA and DHA) that your body is producing in response to your diet. All of the above tagged materials are non-radioactive, non-toxic, and do not pose any health risk to you. Another fasting blood sample will be obtained when you return the next morning.

Twelve-hour fasting blood samples (30ml) will be collected on day 1, 2, 29 and 30 for analyses of plasma lipids. Blood samples obtained on day 1 and 2 will be used to measure baseline values for study endpoints, whereas blood samples obtained on the two last days will be used to measure final endpoint values.

Twelve-hour fasting blood samples (30ml) will be collected on day 1, 2, 29 and 30 for analyses of C-reactive protein and inflammatory cytokines. Blood samples obtained on day 1 and 2 will be used to measure baseline values for study endpoints, whereas blood samples obtained on the two last days will be used to measure final endpoint values.

atherosclerosis/kukuruz

Combined Bioactive Therapy Effects Over Cardiovascular Markers in Statin Treated Patients

Impact of EPA and DHA Supplementation on Plasma Biomarkers of Inflammation (n3)

Canola Oil Multicentre Intervention Trial (COMIT)

Do Fish Oils Prevent Restenosis Post-Coronary Angioplasty?

Najkompletnija baza ljekovitog bilja potpomognuta znanošću